SBIR/STTR Research Award

Novel Agents for the Proliferation of Stem Cells

Award identifier e5a6d57da49d959a49d45cd004987d4673f1841768770524f60a7a7b3c10d9d9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$181,320

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Minerva Biotechnologies Corporation
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Pluripotent (undifferentiated) stem cells possess the ability to become virtually any cell type in the human body and therefore, in principal, could be used to replace damaged tissues in organs that have traditionally b een thought not to have a significant potential for functional self-repair such as heart muscle, spinal cord, brain tissue and kidney. However, to implement these therapies, one must have the ability to identify, isolate and proliferate populations of plur ipotent stem cells. The first problem is that current methods for identifying pluripotent stem cells are insufficient. We have identified a new marker of pluripotency that discriminates between two different cell types within a population that current meth ods identify as being all pluripotent . Secondly, it is difficult to culture embryonic stem cells (ESCs) without initiating differentiation. Growing ESCs under current state of the art protocols will yield only 50-75% undifferentiated colonies. This is in large part due to the fact that they are grown over a layer of feeder cells which secrete poorly understood factors, some of which promote the growth of undifferentiated stem cells and others that undoubtedly trigger differentiation. Factors secreted by neighboring cells influence how pluripotent stem cells differentiate. For example, pluripotent stem cells can be influenced to differentiate into a particular cell type by growing them over tissues of the desired cell type. What is needed is a cell-free s ystem for growing ESCs in which only discrete, well-characterized agents are added to drive their growth. We have succeeded in growing ESCs in a cell-free system by adding a single agent that activates a newly identified growth factor receptor on the surfa ce of ESCs - conditioned media from feeder cells was not added. The resultant population was 100% pluripotent and was signaled to differentiate by the withdrawal of our novel agent. This is a major step toward understanding the molecular drivers that maint ain pluripotency as well as those that initiate differentiation and will enable stem cell therapies that are currently out of reach. Thus the isolation and propagation of pure pools of pluripotent stem cells will be critical for therapeutic applications of stem cell therapy for the repair of brain and spinal cord injuries, diabetes, cardiac failure, retinopathies and further will enable a whole range of therapeutic interventions that are currently not possible. PUBLIC HEALTH RELEVANCE: Pluripotent (undiffer entiated) stem cells possess the ability to become virtually any cell type in the human body and therefore, in principal, could be used to replace damaged tissues in organs that have traditionally been thought not to have a significant potential for functi onal self-repair such as heart muscle, spinal cord, brain tissue and kidney. However, to implement these therapies, one must have the ability to identify, isolate and proliferate populations of pluripotent stem cells. We have succeeded in growing ESCs in a cell-free system by adding a single agent that activates a newly identified growth factor receptor on the surface of ESCs - conditioned media from feeder cells was not added.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.